Floatz logo

Capivasertib

Invasive Breast Cancer

University of NottinghamSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

59 Active assets in the Invasive Breast Cancer cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
University of California, San Francisco
Phase 4BBB
Letrozole
Emory University
Phase 4BBB
Arimidex
Jonsson Comprehensive Cancer Center
Phase 4BBB
EXEMESTANE
University of California, San Francisco
Phase 4BBB
FULVESTRANT
Massachusetts General Hospital
Phase 2BB

View all 50 →

Same molecule, other indications

Capivasertib is also rated in:

triple-negative breast carcinomaDormant
BB
Indicative ·
71 / 100
View asset →
estrogen-receptor positive breast cancerDormant
BB
Indicative ·
70 / 100
View asset →
Advanced Non-small-cell Lung CancerDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →